Net sales for the three months ended February 28, 2009 were $49.45 million, a 21% increase over the $40.72 million reported for the three months ended February 28, 2008.
For the nine months ended February 28, 2009, the company reported net sales of $142.23 million, an increase of 19%, compared to $119.75 million reported for the same period of 2008.
The company reported a net income of $7.03 million or $0.29 per share, for the nine months ended February 28, 2009, compared with $10.4 million or $0.43 per share in the prior year period.
Jan Keltjens, president and CEO of AngioDynamics, said: “We have a strong and growing oncology/surgery business that is in a position to potentially help millions of patients through our exciting IRE technology. We are focusing our efforts with the NanoKnife IRE System on continuing pre-clinical studies to advance the technology and support regulatory filings, enhancing our focus on driving clinical programs towards gaining labeling for specific indications, and building professional education programs.
“We also will be working to build our laser vein ablation business, the Benephit Targeted Renal Therapy product line and our access product lines, as well as reinvigorating our product development effort. Our overall goal is to capitalize on our numerous opportunities while maintaining our business model that generates substantial operating cash flow and positions us to drive a growth strategy through focused internal and external investments.”